Soon enough, there's a big chance that the plucky biotech Coherus Biosciences (NASDAQ: CHRS) is going to be eating 's (NYSE: ABBV) lunch. Assuming it does, it's not going to be stealing a fry from the corner of AbbVie's plate -- it's going for a big-mouth chomp of the cheeseburger with all the fixings. And there's nothing the larger company can do about it. 

AbbVie shareholders are doubtless bracing themselves. But does that mean you should be considering an investment in Coherus? Let's find out.

Coherus develops new oncology drugs with a combination of in-licensing candidates and its own research and development (R&D) activities, but it also currently sells biosimilar drugs that are copies of medicines developed by other companies. While none of its internally developed therapies have been commercialized yet, it has two biosimilars on the market, and it plans to launch three more by the end of 2023. Sales of those biosimilars brought in $211 million in 2022, but its existing portfolio of marketed medicines hasn't been enough to make the company profitable yet. Still, if regulators give it the green light to commercialize its biosimilar to Humira, AbbVie's crown jewel, that could change almost overnight. 

Continue reading

Source Fool.com